Welcome to the John Carroll University Student Health Center!

We require a completed student health form for <u>all</u> students before classes begin.

- 1. Return the completed form to John Carroll University, (for fall semester no later than August 1, spring semester no later than January 1) to the address below, email from your JCU account to jkrevh@jcu.edu, or fax to the number below.
- 2. Include a copy of your medical insurance card -- both sides.
- 3. We strongly recommend that you be immunized against bacterial meningitis by receiving a meningitis vaccine.
- 4. If you have a condition requiring continuing care (e.g. diabetes, hypertension, emotional disorders, seizures), please have your physician send a letter with his/her suggestions for necessary follow-up, medications, etc.
- 5. No physical exam is required.
- 6. **Information for varsity athletes:** All varsity athletes are required to have a physical examination by John Carroll's sports medicine team physician prior to the first scheduled practice. Please check **www.jcusports.com** for additional information pertaining to when physicals are scheduled and insurance information. If you have additional questions, please don't hesitate to e-mail or call Don McPhillips M.S., ATC, LAT, head athletic trainer at dmcphillips@jcu.edu or 216.397.4503.
- 7. If you are under the age of 18, you must have your parent or guardian must fill out this form and sign on page 3.

Student Health Center
1 John Carroll Boulevard
University Heights, OH 44118-4581
Telephone: 216.397.4349 ◆ fax: 216.397.1787

Email: jkrevh@jcu.edu

TO: Student Health Center
John Carroll University
1 John Carroll Boulevard
University Heights, OH 44118
(F) 216.397.1787

Signature



Student Health Record THIS IS A CONFIDENTIAL COMMUNICATION

· ,	Banner ID:
Student Name	Date of Birth//
Home Address	City State
Student Cell Phone ()	City State Zip
Person to be notified in an emergency	Relationship
Home Address	City State Zin
Home Ph () Business Ph (
Please list any FOOD or DRUG allergies you have and ir	nclude the type of reaction:
Please list any medicines which you are taking on a regu	lar basis, including birth control pills:
If you are now receiving allergy injections and plan to cor	ntinue while in school, please indicate: [] yes [] no
Please list any operations you have had and the dates: _	
DDIMARY INSURANCE Policy Holder's Name	Date of Pirth / /
Employer	Date of Birth// Business Phone ()
Health Insurance Carrier	
Health Insurance Carrier's Address	
	Group Number
PERSONAL HISTORY - Have you ever had any of the follower in the state of t	owing? (Comment below if necessary) YES NO
[] [] Chicken Pox [] [] Rheumatic Fever [] [] Heart problem or Cardiac Workup [] [] Urinary Tract Infections [] [] STI (sexually transmitted infections) [] [] Mononucleosis (Mono) [] [] Recurrent Sinus Infections [] [] Recurrent Ear Infections [] [] Pneumonia [] [] Pneumonia [] [] Skin Problems [] [] Arthritis [] [] Arthritis [] [] Thyroid Problems [] [] Stomach or Bowel Problems [] [] Blood Disorder [] [] Orthopaedic Problems [] [] Diabetes	[] [] Asthma or Wheezing w/Bronchitis [] [] Hepatitis or Jaundice [] [] Seizures or Convulsions [] [] High Blood Pressure [] [] HIV Infection [] [] Tuberculosis [] [] Anxiety/Panic Attacks [] [] Depression/Mood Disorders [] [] Alcohol/Drug Abuse [] [] Anorexia/Bulimia [] [] Migraine Headaches [] [] Schizophrenia Tobacco Use: [] [] smoke [] [] Other
Comment	
Student Signature	
Parent/Guardian Consent for Medical Treatment of Child (For studies)	, , , , , , , , , , , , , , , , , , , ,
consent to any x-ray examination, anesthetic, medical or surgical diagnosis or special supervision, and on the advice of, a licensed physician, surgeon, as supervision. I further understand and agree a photocopy of this signed conse	or treatment, and hospital care to be rendered to said child under the genera nesthesiologist, dentist, or other qualified medal personnel acting under thei

Date

undersigned student (18 years of age or older) or parent (studer provided to me about Meningococcal Meningitis and Hepatitis B nated against these diseases. The information below regarding	nt under 18), have read and understand the information. I understand the benefits and risks of being vacci-		
Meningococcal vaccine received: [] yes [] no	Hepatitis B vaccine received: [] yes [] no		
Signature	Date		
Student/Parent or Guardian			
If the student is a minor, please print their name:			

The following pages contain questions regarding your immunization record, followed by the mandated information for Meningitis and Hepatitis B.

Alternatively, you may attach an immunization record previously obtained from your physician or school, **but you must complete the Tuberculosis screening beginning on page 6 of this document**.

Name			
First Name	Middle Name	Last Nan	ne
Street Date of Entry/ [Date of Birth//	City	State Zip
PART II			
	UMPS, RUBELLA) 8 days apart for students born after 1956 at ths or later		
2. Dose 2 given at least 28 day	rs after first dose	#2/_	/
1. OPV alone (oral Sabin three 2. IPV/OPV sequential: IPV #1 3. IPV alone (injected Salk four C. VARICELLA (Birth in the U.S. before 1980, 1. History of Disease 2. Varicella antibody M D 3. Immunization a. Dose #1 b. Dose #2 given at least 12 we	Result: Reactive No#1	H3/ M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y	
should receive one dose of Td 1. Primary series of four doses #1// #2//	P, DT, or Td, and booster with Td or Tdap in ap at an interval as short as 2 years since last with DTaP, DTP, DT, or Td: #3	ast Td as appropriate. Refer to AC munization at least 2-5 years sine M D N M D M D M D (PV) t 0, 2, and 6 month intervals.)	CIP for details) ce last dose of Td, depending on
a. Dose #1/ b. Dos	se #2//_ c. Dose #3// M _ D _ Y	.	

F. HEPATITIS A

1. Immunization (hepatitis A)	
a. Dose #1/ b. Dose #2//	
M D Y M D Y	
2. Immunization (Combined hepatitis A and B vaccine)	
a. Dose #1/ b. Dose #2/ c. Dose #3	JJ
$M D Y \qquad \qquad M D Y \qquad \qquad M$	D Y

G. HEPATITIS B

(All college and health sciences students. Three doses of vaccine or two doses of adult vaccine in adolescents 11-15 years of age, or a positive hepatitis B surface antibody meets the requirement.)
1. Immunization (hepatitis B)
a. Dose #1/ b. Dose #2/ c. Dose #3/
M D Y M D Y M D Y Adult formulation Child formulation
2. Immunization (Combined hepatitis A and B vaccine)
a. Dose #1/ b. Dose #2/ c. Dose #3/
M D Y M D Y
3. Hepatitis B surface antibody Date//
M D Y
Result: Reactive Non-reactive

H. MENINGOCOCCAL TETRAVALENT

(A,C,Y,W-135 / One dose — for college freshmen living in dormitories/residence halls, persons with terminal complement deficiencies or asplenia, laboratory personnel with exposure to aerosolized meningococci, and travelers to hyperendemic or endemic areas of the world. Non-freshmen college students may choose to be vaccinated to reduce their risk of meningococcal disease.)

Tetravalent conjugate (preferred; data for revaccination pending; administer simultaneously with Tdap if possible): Date ___/___

Tetravalent polysaccharide (acceptable alternative if conjugate not _____ M___ D___ Y available; revaccinate every 3-5 years if increased risk continues): Date ____/___ M___ D___ Y

I. TUBERCULOSIS (TB) SCREENING/TESTING Yes Have you ever had a positive TB skin test? Have you ever had close contact with anyone who was sick with TB? Were you born in one of the countries listed below and arrived in the U.S. within the past 5 years? Yes No (If yes, please circle the country) Have you ever traveled** to/in one or more of the countries listed below? Yes No (If yes, please check the country/ies) Have you ever been vaccinated with BCG? No Yes Papua New Guinea Afghanistan Guinea Algeria Guinea-Bissau Paraguay Angola Guyana Peru Anguilla Haiti Philippines Argentina Honduras Poland Armenia India Portugal Azerbaijan Indonesia Qatar Bahamas Iran Romania Russian Federation Bahrain Iraq Bangladesh Japan Rwanda Kazakhstan St. Vincent & Belarus The Grenadines Belize Kenya Benin Kiribati Sao Tome & Principe Bhutan Korea-DPR Saudi Arabia Bolivia Korea-Republic Senegal Bosnia & Herzegovina Seychelles Kuwait Sierra Leone Botswana Kyrgyzstan Singapore Brazil Lao PDR Solomon Islands Brunei Darussalam Latvia Somalia South Africa Spain Lesotho Bulgaria Burkina Faso Liberia Burundi Lithuania Cambodia Macedonia-TFYR Sri Lanka Sudan Cameroon Madagascar Cape Verde Malawi Suriname Central African Rep. Malaysia Syrian Arab Republic Maldives Chad Swaziland China Mali Tajikistan Colombia Marshall Islands Tanzania-UR Comoros Mauritania Thailand Timor-Leste Congo **1**Mauritius Congo DR Mexico Togo Cote d'Ivoire Micronesia Tokelau Croatia Tonga Moldova-Rep. Djibouti Mongolia Tunisia Dominican Republic Montenegro Turkey Ecuador Morocco Turkmenistan Tuvalu Egypt Mozambique Uganda El Salvador Myanmar Ukraine Equatorial Guinea Namibia Eritrea Uruguay Nauru Estonia Nepal Uzbekistan **V**anuatu Ethiopia New Caledonia Venezuela Fiji Nicaragua Viet Nam French Polynesia Niger Gabon Nigeria Wallis & Futuna Islands Gambia Niue W. Bank & Gaza Strip Georgia N. Mariana Islands Yemen Ghana Pakistan Zambia Zimbabwe Guam Palau Guatemala Panama

If the answer is **YES** to any of the above questions, John Carroll University requires that a health care provider complete a tuberculosis risk assessment (to be completed prior to the start of classes).

If the answer to all of the above questions is **NO**, no further testing or further action is required and the questions on pages 7-8 can be disregarded. These pages will need to be printed out and either mailed or faxed in by your physician.

J. TUBERCULOSIS (TB) RISK ASSESSMENT

Persons with any of the following risk factors are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented:

Recent close contact with someone with infectious TB disease Yes No
Foreign-born from (or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America) Yes No
Fibrotic changes on a prior chest x-ray suggesting inactive or past TB disease Yes No
HIV/AIDS Yes No
Organ transplant recipient Yes No
Immunosuppressed (equivalent of > 15 mg/day of prednisone for >1 month or TNF- α antagonist) Yes \square No
History of illicit drug use Yes No
Resident, employee, or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities) Yes No
Medical condition associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin's disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)] Yes No
1. Does the student have signs or symptoms of active tuberculosis disease? Yes No If No, proceed to 2 or 3. If Yes, proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.
2. Tuberculin Skin Test (TST) (TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0".
The TST interpretation should be based on mm of induration as well as risk factors.)**
Date Given:// Date Read://
Result: mm of induration **Interpretation: Positive Negative
Date Given:/ Date Read:/
Result: mm of induration **Interpretation: Positive Negative
3. Interferon Gamma Release Assay (IGRA)
Date Obtained:/ (specify method) QFT-G QFT-GIT other
Result: Positive Negative Intermediate
Date Obtained:/ (specify method) QFT-G QFT-GIT other
M D Y Possitive Desitive Diletermediate
Result: Positive Negative Intermediate 4. Chest x-ray: (Required if TST or IGRA is positive)
Date of chest x-ray:/ Result: Normal Abnormal

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease
- Organ transplant recipients
- Immunosuppressed persons: taking > 15 mg/d of prednisone for > 1 month; taking a TNF- α antagonist
- Persons with HIV/AIDS

>10 mm is positive:

- Persons born in a high prevalence country or who resided in one for a significant* amount of time
- History of illicit drug use
- Mycobacteriology laboratory personnel
- History of resident, worker or volunteer in high-risk congregate settings
- Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes

>15 mm is positive:

• Persons with no known risk factors for TB disease

HEALTH CARE PROVIDER	
Name	Address
Signature	Phone

MENINGOCOCCAL DISEASE AND COLLEGE STUDENTS

Meningococcal disease is a serious illness caused by bacteria. It is the leading cause of bacterial meningitis in children 2-18 years of age in the United States. Meningococcal bacteria can cause meningitis (inflammation of the lining of the brain and spinal cord) or sepsis (an infection of the bloodstream). Symptoms of meningitis include stiff neck, headache, fever, nausea, vomiting, confusion, and drowsiness. Symptoms of sepsis include fever, shock, and coma. Death from sepsis can occur within 12 hours of the beginning of the illness – meningococcal disease can be a rapid and overwhelming infectious disease. For these reasons, meningococcal infections that occur in childcare centers, elementary schools, high schools, and colleges often cause panic in the community. Every year about 2,600 people in the United States are infected with meningococcus. Ten to 15 percent of these people die in spite of treatment with antibiotics. Of those who live, another 10 percent lose their arms or legs, become deaf, have problems with their nervous systems, become mentally retarded or suffer seizures or strokes.

How do you catch meningococcal infection?

Usually meningococcal infection is acquired after intimate contact with an infected person. Intimate contact includes kissing, sharing toothbrushes or eating utensils, or frequently eating or sleeping in the same dwelling as an infected individual.

Who is at risk?

Anyone can get meningococcal disease, but it is most common in infants less than 1 year of age and in people with certain medical conditions. College freshmen, particularly those who live in dormitories, have a slightly increased risk of getting meningococcal disease. The risk for meningococcal disease among nonfreshmen college students is similar to that for the general population; however, the vaccine is safe and effective and therefore can be provided to nonfreshmen undergraduates who want to reduce their risk for meningococcal disease.

What can be done to decrease risk?

The meningococcal vaccine can prevent four types of meningococcal disease. These include two of the three most common types in the United States. Meningococcal vaccine cannot prevent all types of the disease, but it does help to protect people who might become sick if they don't get the vaccine. The vaccine is available through a variety of settings including physician offices and university/college student health centers.

What about the vaccine?

A vaccine, like any other medicine, is capable of causing serious problems, such as allergic reactions. People should not get meningococcal vaccine if they have ever had a serious allergic reaction to a previous dose of the vaccine. Some people who get the vaccine may develop redness or pain where the shot was given, and a small percentage of people develop a fever. These symptoms usually last for one or two days. The risk of the meningococcal vaccine causing serious harm is extremely small. Getting meningococcal vaccine is safer than getting the disease. People who are mildly ill at the time the shot is scheduled, and women who are pregnant, can still get the vaccine. Those with moderate or severe illnesses should usually wait until they recover. College students and their parents should discuss the timing, risks, and benefits of vaccination with their health care providers. For more information about the meningococcal vaccine, access the Vaccine Information Sheet at the Centers for Disease Control and Prevention (CDC) web site http://www.cdc.gov/nip/publications/VIS. If college students decide to be vaccinated against meningococcal meningitis, they (or their parents if they are less than 18 years of age) should contact their health care provider or the university/college student health center where they will be attending to inquire about receiving the vaccine.

Adapted from CDC and the Children's Hospital of Philadelphia Vaccine Education Center publications.

HEPATITIS B AND COLLEGE STUDENTS

Hepatitis B is a serious disease. Hepatitis B is a virus that affects the liver. It is one of several hepatitis diseases (for example, hepatitis A and hepatitis C) that are caused by different viruses but are similar in that they all attack the liver. The hepatitis B virus (HBV) can cause a short-term (acute) illness that leads to loss of appetite, stomach pain, tiredness, diarrhea, vomiting, jaundice (yellow skin or eyes), and pain in muscles and joints. These symptoms can last for several weeks. It can also cause a long-term (chronic) illness from which people never recover. A person might not look or feel sick, but he or she carries the hepatitis B virus in their blood for the rest of their lives and can infect other people with the hepatitis B virus. Chronic hepatitis B may cause liver damage (cirrhosis), liver cancer, and even death. About 1.25 million people in the United States have chronic HBV infection. Each year 80,000 more people, mostly young adults, get infected with HBV and 4,000 to 5,000 people die from chronic hepatitis B.

How do you catch hepatitis B?

Hepatitis B virus is spread through contact with blood or other body fluids of an infected person. You can catch the virus by having unprotected sex, by sharing drug needles or by sharing personal items like razors and toothbrushes with someone who is infected. Babies of chronic HBV mothers can become infected during birth. Children can be infected through exposure to blood and other body fluids from infected children or adults.

Who is at risk?

Anyone who participates in any of the behaviors listed above is at risk of acquiring hepatitis B.

What can be done?

There are hepatitis B vaccines available that can prevent infection from the virus. Many physicians offer the vaccine to patients seen in their offices. These are the first anti-cancer vaccines, because they can prevent a form of liver cancer that can develop in a person who gets a chronic hepatitis B infection.

What about the vaccine?

A vaccine, like any medicine, is capable of causing serious problems, such as allergic reactions. Most people who get the hepatitis B vaccine do not have any problems with it. People who have ever had a life-threatening allergic reaction to baker's yeast (the kind used to make bread) or to a previous dose of hepatitis B vaccine should not get the vaccine. People who are moderately to severely ill at the time the shot is scheduled should usually wait until they recover before getting the vaccine. Hepatitis B vaccine is very safe and the risk of it causing serious harm is extremely small. Hepatitis is a serious disease and getting the vaccine is safer than getting the disease. College students and their parents should discuss the risks and the benefits of vaccination with their health care providers. For more information about the hepatitis vaccine, access the Vaccine Information Sheet at the Center for Disease Control and Prevention (CDC) website http://www.cdc.gov/nip/publications/VIS. If college students decide to be vaccinated against hepatitis B, they (or their parents if they are less than 18 years of age) should contact their health care provider or the university/college student health center where they will be attending to inquire about receiving the vaccine.

Adapted from CDC publications.